844 related articles for article (PubMed ID: 28248701)
1. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
2. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
[TBL] [Abstract][Full Text] [Related]
3. From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time.
van Sonderen A; Schreurs MW; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Autoimmun Rev; 2016 Oct; 15(10):970-4. PubMed ID: 27485013
[TBL] [Abstract][Full Text] [Related]
4. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.
van Sonderen A; Petit-Pedrol M; Dalmau J; Titulaer MJ
Nat Rev Neurol; 2017 May; 13(5):290-301. PubMed ID: 28418022
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex.
Montojo MT; Petit-Pedrol M; Graus F; Dalmau J
Neurologia; 2015 Jun; 30(5):295-301. PubMed ID: 24485651
[TBL] [Abstract][Full Text] [Related]
7. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
Michael S; Waters P; Irani SR
Pract Neurol; 2020 Oct; 20(5):377-384. PubMed ID: 32595134
[TBL] [Abstract][Full Text] [Related]
8. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
van Sonderen A; Schreurs MW; de Bruijn MA; Boukhrissi S; Nagtzaam MM; Hulsenboom ES; Enting RH; Thijs RD; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Neurology; 2016 May; 86(18):1692-9. PubMed ID: 27037230
[TBL] [Abstract][Full Text] [Related]
9. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.
Lang B; Makuch M; Moloney T; Dettmann I; Mindorf S; Probst C; Stoecker W; Buckley C; Newton CR; Leite MI; Maddison P; Komorowski L; Adcock J; Vincent A; Waters P; Irani SR
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):353-361. PubMed ID: 28115470
[TBL] [Abstract][Full Text] [Related]
10. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.
Binks SNM; Klein CJ; Waters P; Pittock SJ; Irani SR
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):526-534. PubMed ID: 29055902
[TBL] [Abstract][Full Text] [Related]
11. Detection of LGI1 and CASPR2 antibodies with a commercial cell-based assay in patients with very high VGKC-complex antibody levels.
Yeo T; Chen Z; Chai JYH; Tan K
J Neurol Sci; 2017 Jul; 378():85-90. PubMed ID: 28566186
[TBL] [Abstract][Full Text] [Related]
12. Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia.
Kannoth S; Nambiar V; Gopinath S; Anandakuttan A; Mathai A; Rajan PK
Neurol Sci; 2018 Mar; 39(3):455-460. PubMed ID: 29264691
[TBL] [Abstract][Full Text] [Related]
13. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
Klein CJ; Lennon VA; Aston PA; McKeon A; O'Toole O; Quek A; Pittock SJ
JAMA Neurol; 2013 Feb; 70(2):229-34. PubMed ID: 23407760
[TBL] [Abstract][Full Text] [Related]
14. Emerging psychiatric syndromes associated with antivoltage-gated potassium channel complex antibodies.
Prüss H; Lennox BR
J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1242-1247. PubMed ID: 27435086
[TBL] [Abstract][Full Text] [Related]
15. A Chinese female Morvan patient with LGI1 and CASPR2 antibodies: a case report.
Zhang L; Lu Q; Guan HZ; Mei JH; Ren HT; Liu MS; Peng B; Cui LY
BMC Neurol; 2016 Mar; 16():37. PubMed ID: 26983964
[TBL] [Abstract][Full Text] [Related]
16. Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.
Vincent A; Pettingill P; Pettingill R; Lang B; Birch R; Waters P; Irani SR; Buckley C; Watanabe O; Arimura K; Kiernan MC
JAMA Neurol; 2018 Dec; 75(12):1519-1527. PubMed ID: 30242309
[TBL] [Abstract][Full Text] [Related]
17. [Current Perspective on Voltage-gated Potassium Channel Complex Antibody Associated Diseases].
Watanabe O
Brain Nerve; 2018 Apr; 70(4):315-328. PubMed ID: 29632280
[TBL] [Abstract][Full Text] [Related]
18. Delayed LGI1 seropositivity in voltage-gated potassium channel (VGKC)-complex antibody limbic encephalitis.
Sweeney M; Galli J; McNally S; Tebo A; Haven T; Thulin P; Clardy SL
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28432047
[TBL] [Abstract][Full Text] [Related]
19. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity.
Malter MP; Frisch C; Schoene-Bake JC; Helmstaedter C; Wandinger KP; Stoecker W; Urbach H; Surges R; Elger CE; Vincent AV; Bien CG
J Neurol; 2014 Sep; 261(9):1695-705. PubMed ID: 24935858
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
